Read more

January 19, 2024
1 min read
Save

Intradialytic hypotension, mortality not linked in younger patients on hemodialysis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • Intradialytic hypotension was present in 2.9% to 61.1% of patients during the study.
  • Overall, 4.5% of the patients died.

Intradialytic hypotension and mortality in adolescents and young adults with kidney failure requiring hemodialysis share no significant connection, a recently published study found.

“Intradialytic hypotension (IDH), or hypotension experienced during dialysis, is common among children and young adults with kidney failure requiring hemodialysis,” Xixi Zhao, MD, of the Center for Academic Medicine, Pediatric Nephrology at the Stanford University School of Medicine, and colleagues wrote. “We examined the association of commonly used definitions of IDH with death in [patients] with kidney failure receiving hemodialysis.”

Arm of child on hospital bed with teddy bear
Intradialytic hypotension was present in 2.9% to 61.1% of patients during the study. Source: Adobe Stock.

In a retrospective observational cohort trial of 1,199 patients aged 10 to 21 years old who were on hemodialysis in a large dialysis clinic, researchers used varying definitions of IDH to classify participants and determine 2-year all-cause mortality.

Patients were deemed to have IDH if the condition was present in at least 30% of hemodialysis treatments during the first 90 days after starting dialysis.

Researchers found no association of IDH with mortality after adjusting for sociodemographic and clinical characteristics, which remained consistent across different age groups and pre-dialysis systolic blood pressure levels. There was also no significant link between examined the dose-response IDH and mortality, according to the researchers.

Researchers examined IDH in different proportions of baseline treatments (from below 5% to more than 50%) and found no dose-response relationship with mortality.

Overall, depending on the definition used, IDH was present in 2.9% to 61.1% of patients and 4.5% of the patients died.

“Future studies should also explore other IDH definitions with mortality and examine the association of IDH with outcomes other than death, as well as mechanisms that may allow this population to better tolerate IDH,” according to Zhao and colleagues.